Hiv Drugs Market 2021 Global Industry Analysis, Potential Growth, Key Players
編輯歷史
| 時間 | 作者 | 版本 |
|---|---|---|
| 2021-08-04 04:14 – 04:15 | r1 – r2 | |
顯示 diff- Untitled
+ Hiv Drugs Market 2021 Global Industry Analysis, Potential Growth, Key Players
+ The global HIV/AIDS drugs market size is likely to derive growth form the increasing prevalence of the disease across the world. According to a report published by Fortune Business Insights, titled “HIV/AIDS Drugs Market: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 25,314.0 Mn in 2018. Fortune Business Insights has predicted that the market will reach US$ 40,675.0 Mn by 2026, thereby exhibiting a CAGR of 6.1% in the forecast period
- This pad text is synchronized as you type, so that everyone viewing this page sees the same text. This allows you to collaborate seamlessly on documents!
+
+ For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/hiv-aids-drugs-market-101115
+ Leading Players operating in the Hiv Drugs Market are:
+
+ Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
+
+
+ *ViiV Healthcare
+ *Gilead Sciences
+ *Merck Sharp & Dohme
+ *Bristol-Myers Squibb Company
+ *Janssen Pharmaceuticals
+ *Theratechnologies
+ *Mylan Pharmaceuticals
+ *Genentech
+ *AbbVie
+ Detailed Table of Content:
+
+ 1. Introduction
+ 1.1. Research Scope
+ 1.2. Market Segmentation
+ 1.3. Research Methodology
+ 1.4. Definitions and Assumptions
+ 2. Executive Summary
+ 3. Market Dynamics
+ 3.1. Market Drivers
+ 3.2. Market Restraints
+ 3.3. Market Opportunities
+ 4. Key Insights
+ 4.1. Epidemiology of HIV/AIDS by Key Countries
+ 4.2. Overview of Pipeline Analysis
+ 4.3. Regulatory Scenario by Key Countries
+ 4.4. Pricing Analysis
+ 4.5. Key Strategies Employed by Market Leaders in Various Regions
+ 4.6. Overview of New Product Launches
+ 5. Global HIV-AIDS Drugs Market Analysis, Insights and Forecast, 2015-2026
+ 5.1. Key Findings / Summary
+ 5.2. Market Analysis, Insights and Forecast – By Drug Class
+ 5.2.1.Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
+ 5.2.2.Integrase Inhibitors
+ 5.2.3.Combination HIV Medicines
+ 5.2.4.Others
+ 5.3. Market Analysis, Insights and Forecast – By Distribution Channel
+ 5.3.1.Hospital Pharmacies
+ 5.3.2.Retail Pharmacies
+ 5.3.3.Online Pharmacies
+ 5.3.4.Others
+ 5.4. Market Analysis, Insights and Forecast – By Region
+ 5.4.1.North America
+ 5.4.2.Europe
+ 5.4.3.Asia Pacific
+ 5.4.4.Rest of World
+ 6. North America HIV-AIDS Drugs Market Analysis, Insights and Forecast, 2015-2026
+ 6.1. Key Findings / Summary
+ 6.2. Market Analysis – By Drug Class
+ 6.2.1.Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
+ 6.2.2.Integrase Inhibitors
+ 6.2.3.Combination HIV Medicines
+ 6.2.4.Others
+ 6.3. Market Analysis – By Distribution Channel
+ 6.3.1.Hospital Pharmacies
+ 6.3.2.Retail Pharmacies
+ 6.3.3.Online Pharmacies
+ 6.3.4.Others
+ 6.4. Market Analysis – By Country
+ 6.4.1.U.S.
+ 6.4.2.Canada
+ 7. Europe HIV-AIDS Drugs Market Analysis, Insights and Forecast, 2015-2026
+ 7.1. Key Findings / Summary
+ 7.2. Market Analysis – By Drug Class
+ 7.2.1.Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
+ 7.2.2.Integrase Inhibitors
+ 7.2.3.Combination HIV Medicines
+ 7.2.4.Others
+ 7.3. Market Analysis – By Distribution Channel
+ 7.3.1.Hospital Pharmacies
+ 7.3.2.Retail Pharmacies
+ 7.3.3.Online Pharmacies
+ 7.3.4.Others
+ 7.4. Market Analysis – By Country/ Sub-Region
+ 7.4.1.U.K.
+ 7.4.2.Germany
+ 7.4.3.France
+ 7.4.4.Spain
+ 7.4.5.Italy
+ 7.4.6.Scandinavia
+ 7.4.7.Rest of Europe
|
||
| 2021-08-04 04:14 | r0 | |
顯示 diff+ Untitled
+ This pad text is synchronized as you type, so that everyone viewing this page sees the same text. This allows you to collaborate seamlessly on documents!
|
||